Short Interest in Sensus Healthcare, Inc. (NASDAQ:SRTS) Rises By 20.0%

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 583,500 shares, a growth of 20.0% from the November 30th total of 486,100 shares. Based on an average trading volume of 174,600 shares, the days-to-cover ratio is presently 3.3 days. Currently, 4.4% of the company’s stock are sold short.

Analyst Ratings Changes

Several research firms recently commented on SRTS. Maxim Group raised their price target on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, November 15th. HC Wainwright lifted their target price on shares of Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, November 18th.

Sensus Healthcare Stock Down 1.8 %

Shares of SRTS traded down $0.13 during midday trading on Friday, reaching $7.21. 318,480 shares of the stock were exchanged, compared to its average volume of 273,869. The company has a market cap of $118.16 million, a price-to-earnings ratio of 12.65 and a beta of 1.16. Sensus Healthcare has a 12-month low of $2.36 and a 12-month high of $9.33. The firm has a 50 day simple moving average of $7.61 and a 200-day simple moving average of $6.57.

Hedge Funds Weigh In On Sensus Healthcare

A number of hedge funds have recently added to or reduced their stakes in the company. Truvestments Capital LLC acquired a new position in Sensus Healthcare during the third quarter worth $32,000. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare during the 2nd quarter valued at about $95,000. Cubist Systematic Strategies LLC bought a new position in shares of Sensus Healthcare in the 2nd quarter valued at approximately $156,000. Acadian Asset Management LLC lifted its holdings in Sensus Healthcare by 578.6% in the 2nd quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock worth $239,000 after purchasing an additional 38,474 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in Sensus Healthcare by 152.4% during the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock worth $412,000 after purchasing an additional 46,732 shares during the period. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.